142 related articles for article (PubMed ID: 17947643)
21. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of endogenous MHC class II-restricted antigen presentation by tacrolimus (FK506) via FKBP51.
Imai A; Sahara H; Tamura Y; Jimbow K; Saito T; Ezoe K; Yotsuyanagi T; Sato N
Eur J Immunol; 2007 Jul; 37(7):1730-8. PubMed ID: 17523132
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
Shibagaki N; Udey MC
J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
[TBL] [Abstract][Full Text] [Related]
24. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.
Eriksson K; Sun JB; Nordström I; Fredriksson M; Lindblad M; Li BL; Holmgren J
Eur J Immunol; 2004 May; 34(5):1272-81. PubMed ID: 15114660
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity.
Kim KW; Kim SH; Jang JH; Lee EY; Park SW; Um JH; Lee YJ; Lee CH; Yoon S; Seo SY; Jeong MH; Lee ST; Chung BS; Kang CD
Cancer Immunol Immunother; 2004 Apr; 53(4):315-22. PubMed ID: 14685778
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.
Martinez-Kinader B; Lipford GB; Wagner H; Heeg K
Immunology; 1995 Oct; 86(2):287-95. PubMed ID: 7490131
[TBL] [Abstract][Full Text] [Related]
27. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
28. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.
Okada N; Saito T; Masunaga Y; Tsukada Y; Nakagawa S; Mizuguchi H; Mori K; Okada Y; Fujita T; Hayakawa T; Mayumi T; Yamamoto A
Cancer Res; 2001 Nov; 61(21):7913-9. PubMed ID: 11691812
[TBL] [Abstract][Full Text] [Related]
29. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
Schnell S; Young JW; Houghton AN; Sadelain M
J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
[TBL] [Abstract][Full Text] [Related]
30. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
31. Effects of mizoribine on MHC-restricted exogenous antigen presentation in dendritic cells.
Song Y; Han S; Kim H; Kim K; Kwon J; Lee SJ; Ha NJ; Lee YH; Lee CK; Kim K
Arch Pharm Res; 2006 Dec; 29(12):1147-53. PubMed ID: 17225465
[TBL] [Abstract][Full Text] [Related]
32. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
33. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
34. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo.
Böhm W; Schirmbeck R; Elbe A; Melber K; Diminky D; Kraal G; van Rooijen N; Barenholz Y; Reimann J
J Immunol; 1995 Oct; 155(7):3313-21. PubMed ID: 7561024
[TBL] [Abstract][Full Text] [Related]
35. Macrophage-colony stimulating factor enhances MHC-restricted presentation of exogenous antigen in dendritic cells.
Han S; Song Y; Lee YH; Lee YR; Lee CK; Cho K; Kim K
Cytokine; 2005 Dec; 32(5):187-93. PubMed ID: 16303313
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylserine receptor-mediated recognition of archaeosome adjuvant promotes endocytosis and MHC class I cross-presentation of the entrapped antigen by phagosome-to-cytosol transport and classical processing.
Gurnani K; Kennedy J; Sad S; Sprott GD; Krishnan L
J Immunol; 2004 Jul; 173(1):566-78. PubMed ID: 15210818
[TBL] [Abstract][Full Text] [Related]
37. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
38. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules.
Harding CV; Song R
J Immunol; 1994 Dec; 153(11):4925-33. PubMed ID: 7963555
[TBL] [Abstract][Full Text] [Related]
39. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
40. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
